Advertisement

Die Indikationen zur Splenektomie

  • H. Barkve

The Indications for Splenectomy

Summary

As an introduction, splenectomy for hemolytic diseases is discussed briefly. The best results of splenectomy are seen in hereditary spherocytosis. The indications for surgery are clear when objective symptoms of the disease are evident. However, even in oligo-symptomatic carriers of this red blood cell abnormality splenectomy must be considered, since hemolytic crises may occur.

Only in the “major” forms of hereditary elliptocytosis splenectomy is indicated. In hereditary non-spherocytic hemolytic anemia, thalassemia major and sickle cell anemia splenectomy is of very limited value. The acquired hemolytic anemias represent a heterogeneous group and a precise diagnosis is essential in every case. When splenectomy is considered it should be preceded by isotope studies. As many as 50% of the patients with chronic, acquired, autoimmune hemolytic anemia can be clinically cured by splenectomy. The others may continue to hemolyze, with prednisone often being ineffective.

In essential thrombocytopenia in which the platelet levels are so low that danger of hemorrhage exists, the indication for splenectomy is clear. In order to exclude from surgery the post-infectious thrombocytopenias of short duration, it is worthwhile to observe the patients for a limited period of time. If the patient, however, still requires relatively high doses of steroids after 2 to 3 months, it is not wise to postpone the operation any longer.

Splenectomy for pancytopenia is indicated only when all other methods of treatment have been exhausted. The result of such an operation is not usually good.

Finally, a number of diseases which are associated with hypersplenism are briefly discussed. Special attention is devoted to two disorders in this group. These are the lympho-proliferative diseases and myelofibrosis.

Hitherto there is no evidence that a patient with a lymphoma of the spleen can be cured by splenectomy. However, in view of the hypersplenism that may occur in the later stages of the disease and because of the lack of response to any other forms of therapy, it is recommended that splenectomy be done early in the course of the disease.

Splenectomy is indicated in myelofibrosis in which thrombocytopenia is severe. In the event of added pronounced hemolysis one must carry out studies with 51Cr-labeled red blood cells in order to determine whether red cell destruction in the spleen is greater than erythropoiesis. Early splenectomy should always be considered.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Amorosi, E. L., Ultmann, J. E.: Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 45, 139–159 (1966).Google Scholar
  2. Bouroncle, B. A., Doan, C. A.: Myelofibrosis, clinical, hematologic and pathologic study of 110 patients. Amer. J. med. Sci. 243, 697–715 (1962).PubMedCrossRefGoogle Scholar
  3. Buchman, J. G., De Gruchy, G. C.: Splenectomy in chronic lymphatic leukemia and lymphosarcoma. Med. J. Aust. 2, 6–12 (1967).Google Scholar
  4. Carpenter, A. F., Wintrobe, M. M., Fuller, E. A., Haut, A., Cartwright, G. E.: Treatment of idiopathic thrombocytopenic purpura. J. Amer. med. Ass. 171, 1911–1916 (1959).CrossRefGoogle Scholar
  5. Crosby, W. H., Whelan, T. J., Heaton, L. D.: Splenectomy in elderly. Med. Clin. N. Amer. 50, 1533–1558 (1966).PubMedGoogle Scholar
  6. Dacie, J. V.: The haemolytic anemias, part 2, 2nd ed. London: J. & A. Churchill Ldt. 1962.Google Scholar
  7. Doan, C. A., Bouroncle, B. A., Wiscman, B. K.: Idiopathic and secondary thrombocytopenic purpura: clinical study and evaluation of 381 cases over a period of 28 years. Ann. intern. Med. 53, 861–876 (1960).Google Scholar
  8. Fisher, J. H., Welch, C. S., Dameshek, W.: Splenectomy in leukemia and leukosarcoma. New Engl. J. Med. 246, 477–484 (1952).PubMedCrossRefGoogle Scholar
  9. Fishman, N., Ballinger, W. F.: Splenectomy for agnogenic myeloid metaplasia and myelofibrosis. Arch. Surg. 90, 240–246 (1965).PubMedCrossRefGoogle Scholar
  10. Flatow, F., Freireich, E. J.: Effect of splenectomy on the response to platelet transfusion in three patients with aplastic anemia. New Engl. J. Med. 274, 242–248 (1966).PubMedCrossRefGoogle Scholar
  11. Gall, E. G.: The surgical treatment of malignant lymphoma. Ann. Surg. 118, 1064–1070 (1943).PubMedCrossRefGoogle Scholar
  12. Gehrmann, G.: Hämolyse und hämolytische Anämien, S. 1–323. Stuttgart: Georg Thieme 1969.Google Scholar
  13. Gupta, T. D., Coombes, B., Brasfield, R. D.: Primary malignant neoplasma of the spleen. Surg. Gynec. Obstet. 120, 947–960 (1965).Google Scholar
  14. Han, T., Ezdinli, E. Z., Sokal, J. E.: Complete remission in chronic lymphocytic leukemia and leukolymphosarcoma. Cancer (Philad.) 20, 243–253 (1967).CrossRefGoogle Scholar
  15. Heaton, L. D., Crosby, W. H., Cohen, A.: Splenectomy in the treatment of hypoplasia of the bone marrow. Ann. Surg. 146, 637–660 (1957).PubMedCrossRefGoogle Scholar
  16. Hickling, R. A.: Giant follicle lymphoma of the spleen — a condition closely related to lymphatic leukemia but apparently curable by splenectomy. Brit. med. J. 1964II, 787–790.Google Scholar
  17. Holt, J. M., Witts, L. J.: Splenectomy in leukemia and the reticuloses. Quart. J. Med., New Ser. 35, 369–383 (1966).Google Scholar
  18. Jensen, M. K.: Splenectomy in myelofibrosis. Acta med. scand. 175, 533–544 (1964).PubMedCrossRefGoogle Scholar
  19. Meyers, M. C.: Results of treatment in 71 patients with idiopathic thrombocytopenic purpura. Amer. J. med. Sci. 242, 295–302 (1961).PubMedCrossRefGoogle Scholar
  20. Mittelman, A., Stutzman, L., Grace, J. T.: Splenectomy in malignant lymphoma and leukemia. Geriatrics 23, 142–149 (1968).PubMedGoogle Scholar
  21. Molander, D. W., Pack, G. T.: Lymphosarcoma: choice of treatment and end-results in 567 patients. Role of surgical treatment for cure and palliation. Rev. Surg. 20, 3–31 (1963).PubMedGoogle Scholar
  22. Nordöy, A., Neset, G.: Splenectomy in hematologic diseases. Acta med. scand. 183, 117–126 (1968).PubMedCrossRefGoogle Scholar
  23. Sandusky, W. R., Leawell, B. S., Benjamin, B. J.: Splenectomy: indications and results in hematologic disorders. Ann. Surg. 159, 695–710 (1964).PubMedCrossRefGoogle Scholar
  24. Silverstein, M. N., Gomes, M. R., Remine, W. H., Elveback, L. R.: Agnogenic myeloid metaplasia. Natural history and treatment. Arch, intern. Med. 120, 546–550 (1967).PubMedCrossRefGoogle Scholar
  25. Smith, D. F., Klopp, C. T.: The value of surgical removal of localized lymphomas. Surgery 49, 469–476 (1960).Google Scholar
  26. Strumia, M. M., Strumia, P. V., Bassert, D.: Splenectomy in leukemia: hematologic and clinical effects on 34 patients and review of 299 published cases. Cancer Res. 26, part 1, 519–528 (1966).Google Scholar
  27. Welch, C. S., Dameshek, W.: Splenectomy in blood dyscrasias. New Engl. J. Med. 242, 601 (1950).PubMedCrossRefGoogle Scholar
  28. Wintrobe, M. M.: Clinical haematology, 5th ed. London: Lea & Febiger 1961.Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1970

Authors and Affiliations

  • H. Barkve
    • 1
  1. 1.Med. Abt. A. RikshospitaletOsloNorway

Personalised recommendations